

## RSPO3-Fc Fusion Protein Conditioned medium

Catalog R001 - 200 ml Lot 4711 Life Sciences Incubator Yalelaan 62 3584 CM Utrecht The Netherlands

Product: RSPO3-Fc Fusion Protein

Product code: R001

Batch: 4711

Concentration  $(mg/L)^*$ : 50 (> 40)

( $\mu$ M): 0.60 (based on the dimeric stoichiometry)

Volume / aliquot (ml): 2 x 100

Yield (mg): 2 x 5.0

Purity (%): > 50 (> 25) Endotoxin (EU/ml): <5.0 (<10)

Label: R001

hRSPO3-Fc Fusion protein Conditioned medium

Batch 4711

Buffer: Conditioned medium

Storage temperature (oC): -80

Shipping: Dry ice

Project manager: Wieger Hemrika QC officer: Roland Romijn

RAP Romyn

\* Determined by LabChip capillary electrophoresis

PRODUCT USE LIMITATIONS, WARRANTY, DISCLAIMER

ImmunoPrecise Antibodies' products contain chemicals which may be harmful if misused. Due care should be exercised with all ImmunoPrecise products to prevent direct human contact. All products are intended For Research Use Only and ARE NOT ALLOWED FOR USE IN HUMANS. Each product is shipped with documentation stating specifications and other technical information. ImmunoPrecise products are warranted to meet or exceed the stated specifications. ImmunoPrecise' sole obligation and the customer's sole remedy is limited to replacement of products free of charge in the event products fail to perform as warranted. ImmunoPrecise makes no other warranty and SPECIFICALLY DISCLAIMS AND EXCLUDES ALL OTHER WARRANTIES OF ANY KIND OR NATURE WHATSOEVER, DIRECTLY OR INDIRECTLY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE SUITABILITY, PRODUCTIVITY, DURABILITY, FITNESS FOR A PARTICULAR PURPOSE OR USE, MERCHANTABILITY, CONDITION, OR ANY OTHER MATTER WITH RESPECT TO IMMUNOPRECISE PRODUCTS. In no event shall ImmunoPrecise be liable for claims for any other damages, whether direct, incidental, foreseeable, consequential, or special (including but not limited to loss of use, revenue or profit), whether based upon warranty, contract, tort (including negligence) or strict liability arising in connection with the sale or the failure of ImmunoPrecise Antibodies products to perform in accordance with the stated specifications.

Version 02/2021 page 1/1